US FDA declines to approve Unicycive's drug for dialysis patients
US FDA declines to approve Unicycive's drug for dialysis patients June 30 (Reuters) - The U.S. Food and Drug Administration declined to approve Uniycive Therapeutics' UNCY.O drug to treat elevated phosphate levels in chronic kidney disease patients on dialysis, the company said on Tuesday.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shinjini Ganguli)
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss